Computerized clinical decision support systems improve care in emergency department

Computerized clinical decision support systems (CCDSSs) are meant to improve efficiency, but evidence of such a positive impact is scarce. In a study published by the Journal of the American Medical Informatics Association, researchers evaluated the impact of CCDSSs in emergency department (EDs).

Led by Paula Bennett of the United Kingdom-based Greater Manchester Academic Health Science Network, the study evaluated international literature using Medline, Cumulative Index of Nursing and Allied Health Literature.

A total of 23 studies, which included the comparison of using CCDSS with face-to-face care in the ED, were included in the analysis. Results showed that half the studies included a significant improvement in clinical care with the use of CCDSS, while the other half showed a slight improvement in care, mainly in the area of documentation.

However, researchers note the quality of the studies’ methodologies to be poor, stating “the quality of the research in approximately 75% of the studies was poor, and therefore conclusions cannot be drawn from these results. However, the studies with a more robust design show evidence of the positive impact of CCDSSs on ED patient care.”

“This is the first review to consider the role of CCDSSs in emergency care and expose the research in this area,” concluded Bennett and colleagues. “The role of CCDSSs in emergency care may provide some solutions to the current challenges in EDs, but further high-quality research is needed to better understand what technological solutions can offer clinicians and patients.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.